At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 109 enrolled
Drug / intervention
risedronatedrug
Likely dose
risedronate 35 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effect of Bisphosphonate on Bone Mass and Bone Turnover in Elderly, Postmenopausal Women With Breast Cancer Following Initiation of Aromatase Inhibitor Therapy
In Brief
A Phase 4 clinical trial evaluating risedronate for Bone Loss and 2 related conditions. Completed, enrolled 109 participants across 1 site.
Detailed Summary
Elderly, postmenopausal women with breast cancer on aromatase inhibitors are at increased risk of developing bone loss and osteoporosis. We postulate that in elderly, osteopenic postmenopausal women who are on aromatase inhibitor therapy, bisphosphonate therapy will (1) prevent bone loss at clinically relevant sites, such as the spine and hip and (2) decrease bone turnover.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBone Loss, Osteoporosis, Breast Cancer
CountriesUnited States
CollaboratorsUniversity of Pittsburgh
Timeline
Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 2007
Enrollment StartSep 2007
Primary CompletionMar 2013
TodayJul 2026
First PostedJun 13, 2007
Enrollment StartSep 1, 2007
Primary CompletionMar 1, 2013
TodayJul 2, 2026
Enrollment to primary: 5.5 yearsPosted 19.1 years ago
Interventions
risedronatedrug
risedronate 35 mg per week